Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2023 Sep;38(9):e6002.
doi: 10.1002/gps.6002.

Effects of lithium on serum Brain-Derived Neurotrophic Factor in Alzheimer's patients with agitation

Deborah A Deliyannides  1   2 , Jamie A Graff  1 , Izael Niño  1 , Seonjoo Lee  2   3   4 , Mustafa M Husain  5 , Brent P Forester  6 , Elizabeth Crocco  7 , Ipsit V Vahia  6 , Davangere P Devanand  1   2   8
Affiliations
Randomized Controlled Trial

Effects of lithium on serum Brain-Derived Neurotrophic Factor in Alzheimer's patients with agitation

Deborah A Deliyannides et al. Int J Geriatr Psychiatry. 2023 Sep.

Abstract

Background: There is ample evidence in animal models that lithium increases Brain-Derived Neurotrophic Factor (BDNF) with supporting evidence in human studies. Little is known, however, about the effects of lithium on BDNF in Alzheimer's Dementia (AD). In one study of patients with Mild Cognitive Impairment, serum BDNF increased after treatment with lithium. These patients also showed mild improvement in cognitive function.

Objectives: To evaluate low-dose lithium treatment of agitation in Alzheimer's disease (AD).

Method: We measured levels of BDNF in patients treated with lithium prior to and after a 12-week randomized placebo-controlled trial.

Results: BDNF levels did not change significantly and were not associated with improvement in overall neuropsychiatric symptoms or in cognitive function.

Conclusions: More research is needed to understand the potential effects of lithium on BDNF in AD including whether its use might be dependent on the stage of cognitive decline and dementia.

Trial registration: ClinicalTrials.gov NCT02129348.

Keywords: Alzheimer's disease; BDNF; agitation; brain-derived neurotrophic factor; dementia; lithium; mild cognitive impairment; neuropsychiatric symptoms; psychiatry.

PubMed Disclaimer

References

REFERENCES

    1. Scheltens P, Blennow K, Breteler M, et al. Alzheimer's disease [Internet]. Lancet. 2016;388(10043):505-517. U.S. National Library of Medicine; [cited 2023Mar23]. https://pubmed.ncbi.nlm.nih.gov/26921134/
    1. Selkoe DJ. Alzheimer’s disease is a synaptic failure. Science. 2002;298(5594):789-791. https://doi.org/10.1126/science.1074069
    1. Laske C, Stransky E, Leyhe T, et al. Stage-dependent BDNF serum concentrations in alzheimer's disease [Internet]. In: Richartz E, ed. Journal of neural transmission. U.S. National Library of Medicine; 1996. [cited 2023Mar23]. https://pubmed.ncbi.nlm.nih.gov/16362629/
    1. Ted Kheng Siang N, Su Hui Ho C, Wai San Tam W, Ee Heok K, Chun-Man Ho R. Decreased serum brain-derived neurotrophic factor (BDNF) levels in patients with alzheimer's disease (AD): a systematic review and meta-analysis [Internet]. Int J Mol Sci. 2019;20(2):257. U.S. National Library of Medicine; [cited 2023Mar23]. https://doi.org/10.3390/ijms20020257
    1. Siuda J, Patalong-Ogiewa M, Żmuda W, et al. Cognitive impairment and BDNF serum levels [Internet]. Neurol Neurochir Pol. 2017;51(1):24-32. U.S. National Library of Medicine; [cited 2023Mar23]. https://doi.org/10.1016/j.pjnns.2016.10.001

Publication types

Associated data